Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Anlotinib + Sintilimab
Indication/Tumor Type cervical cancer
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive cervical cancer predicted - sensitive Anlotinib + Sintilimab Phase II Actionable In a Phase II study, a combination of Anlotinib (AL-3818) and Sintilimab (IBI308) resulted in an objective response rate of 54.8% (23/42, 2 complete responses and 21 partial responses) in CD274 (PD-L1)-positive recurrent or metastatic cervical cancer patients, and led to a disease control rate of 88.1% (37/42, 14 with stable disease), a median progression-free survival (PFS) of 9.4 mos and a 6-mo PFS rate of 73.1%, a median overall survival (OS) not reached, and a 12-mo OS rate of 73.8% (PMID: 35192397). 35192397
PubMed Id Reference Title Details
(35192397) Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. Full reference...